26754-76-7

Usage

Uses

Used in Pharmaceutical Industry:
3,5-Dichloro-2,6-dihydroxybenzoic acid is used as an intermediate in the synthesis of various pharmaceuticals. Its unique structure allows it to be a key component in the development of new drugs, contributing to the advancement of medicinal chemistry.
Used in Dye Industry:
In the dye industry, 3,5-dichlor0-2,6-dihydroxybenzoic acid is used as a precursor for the production of dyes. Its chemical properties enable it to be a vital building block in the creation of a wide range of dyes with different color characteristics.
Used in Organic Compounds Synthesis:
3,5-Dichloro-2,6-dihydroxybenzoic acid is used as a starting material for the synthesis of other organic compounds. Its versatile structure makes it a valuable asset in the development of new organic molecules for various applications.
Used in Medicine:
3,5-Dichloro-2,6-dihydroxybenzoic acid is used in medicine due to its antioxidant properties. Its potential applications in this field may include the development of treatments for various diseases and conditions where oxidative stress plays a role.
Used in Food Preservation:
3,5-Dichloro-2,6-dihydroxybenzoic acid may have potential applications in food preservation. Its antioxidant properties could be harnessed to extend the shelf life of food products and maintain their quality over time.

Upstream product

• 303-07-1 2,6-Dihydroxybenzoic acid 

Downstream Products

• 372110-88-8 N-(4-carbethoxyphenyl)-3,5-dichloro-2,6-dihydroxybenzamide 
• 90793-91-2 methyl 3,5-dichloro-2,6-dimethoxybenzoate 
• 89894-57-5 3,5-Dichlor-2-hydroxy-6-methoxy-benzoesaeure 

Relevant academic research and scientific papers

Salicylate activity. 3. Structure relationship to systemic acquired resistance

Salicylic acid (2-hydroxybenzoic acid; SA) is a primary signal inducing plant defenses against pathogens. This plant disease resistance, known as systemic acquired resistance (SAR), is an attractive target for the development of new plant protection agents. SAR induction is a multistep process that includes accumulation of pathogenesis-related (PR) proteins. The structure-activity profile of salicylates and related compounds has been evaluated using an inducible PR protein (PR-1a) and plant resistance to tobacco mosaic virus (TMV) as markers. Among the 47 selected monosubstituted and multiple-substituted salicylate derivatives tested, all 8 derivatives that induced more PR-1a protein than SA were fluorinated or chlorinated in the 3- and/or 5-position (3,5-difluorosalicylate > 3-chlorosalicylate > 5-chlorosalicylate > 3,5-dichlorosalicylate > 3-chloro-5-fluorosalicylate > 3-fluorosalicylate > 3-fluoro-5-chlorosalicylate > 3,5-dichloro-6-hydroxysalicylate > SA). In general, substitutions for or on the 2-hydroxyl group or at the 4-position of the ring reduced or eliminated PR-1a protein induction. In contrast, substitutions in positions ortho (3-position) or para (5-position) to the hydroxyl group with electron-withdrawing groups other than chlorine or fluorine decreased induction, and electron-donating groups in these positions also had a deleterious effect on PR-1a induction. PR-1a protein accumulation and reduction in TMV lesion diameter exhibited a log-linear relationship. The seven salicylate derivatives that were the most active TMV resistance inducers were all halogenated in the 3- and/or 5-position (3-chlorosalicylate > 3,5-difluorosalicylate > 3,5-dichloro-6-hydroxysalicylate > 3,5,6-trichlorosalicylate > 5-chlorosalicylate > 5-fluorosalicylate > 3,5-dichlorosalicylate > 4-fluorosalicylate > 3-fluorosalicylate > 3-chloro-5-fluorosalicylate > 4-chlorosalicylate > SA). The correlation between PR-1a protein induction and resistance to TMV confirms the value of using PR-1a induction as a screening tool for developing new plant disease control agents.

Phosphate transport inhibitors

Dihydroxybenzamides, useful for treatment of chronic renal failure and uremic bone disease, are disclosed.